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Introduction 12
Chordoma is a rare bone cancer with an annual incidence of 1 in 1,000,000 people and a poor 13 prognosis. It occurs mostly in the spine and whilst surgical resection is currently the most effective 14 treatment this is difficult due to proximity to important structures. Chordomas are largely refractory 15 to current chemotherapy, therefore, there is a pressing unmet clinical need for effective treatments 16 (Stacchiotti & Sommer, 2015) . Recently, the transcription factor Brachyury was identified as a 17 primary drug target in chordoma (Sharifnia et al., 2019) . 18
All-trans retinoic acid (ATRA) is available as a generic drug and is used as a differentiation agent to 19 treat acute promyelocytic leukaemia (APL; Fey & Buske, 2013). U-CH1 chordoma cells treated with 20
ATRA have reduced levels of TBXT (Brachyury gene) mRNA and reduced proliferative capacity 21 (Aydemir et al., 2012) . This study extends and validates these findings offering further insight into 22 the mechanisms of ATRA as a potential chordoma therapeutic agent. 23
Objective 24
The finding that ATRA reduces levels of TBXT (Brachyury) mRNA and reduces proliferative capacity 25 opens three important questions. Firstly, does the reduction in mRNA levels feed through to 26 measurable reduction in Brachyury protein? Secondly, is this effect of ATRA specific to the previously 27 tested chordoma cell line, or is it a universal feature of chordoma cells? Finally, is the reduced 28 proliferative capacity induced by ATRA in chordoma cells, which correlates to Brachyury loss, 29 accompanied by the morphological changes observed following specific siRNA-mediated Brachyury 30 depletion? The objectives of this current study are to address these outstanding and important 31 questions. 32
Methods and materials 33
Cell culture and drug treatment. U-CH1 and JHC7 were obtained from ATCC and cultured as per ATCC 34 guidelines. For all experiments described, 7.75 x10 4 cells were seeded in each well of a 6 well plate. 35 ATRA (Abcam) and DMSO (Sigma Aldrich) were added to the concentrations specified. Drug and 36 media were refreshed every 3 days. Cell counting was performed using a TC20 cell counter (Biorad). 37
Cells were imaged using an Evos Core microscope (AMG). 38
Protein extraction and western blot. Protein was extracted using M-PER buffer (ThermoFisher 39
Scientific) according to the manufacturer's instructions. Samples were denatured in Bolt LDS Sample 40 buffer and Reducing Agent and run on an SDS-polyacrylamide pre cast gel (Bolt 4-12% Bis-Tris Plus, 41
Life Technologies). Samples were transferred onto PVDF membrane in Towbin buffer (10% 42 methanol) and the membrane was blocked in blocking solution (10% skimmed milk in PBS 0.1% 43 Tween20). The membrane was incubated with primary antibody in blocking solution overnight and 44 the membrane was incubated with secondary antibody at room temperature for 2 hours. Primary 45 antibodies used were anti-Brachyury (Abcam, ab209665) and anti-GapDH (Santa Cruz, sc365062). 46
Secondary (HRP linked) antibodies used were: anti-rabbit IgG (CST, 7074S), anti-mouse IgG (CST, 47 7076S). 48
Results 49
Treatment of chordoma cells with ATRA reduces Brachyury levels. JHC7 and U-CH1 chordoma cells 50
were treated with 10 or 20 M ATRA. ATRA caused a reduction in Brachyury levels in both lines, 51
although this was less pronounced in JHC7 (Fig.1) . 52
Treatment of chordoma cells with ATRA causes reduced proliferative capacity and morphological 53
differentiation. U-CH1 cells treated with ATRA have reduced proliferative capacity (Aydimer et al., 54 2012). We treated U-CH1 cells with 20 M ATRA and this resulted in the cell culture failing to 55 increase cell numbers, assumed to be a proliferative inhibition, thus validating the original study ( Fig.  56 2). To extend this we assessed whether there were any morphological changes apparent 57 commensurate with those previously observed following specific siRNA-mediated Brachyury 58 depletion (Hsu et al., 2011) . ATRA treatment resulted in a loss of the physaliferous phenotype and 59 the cells became more elongated and branching (Fig. 3) . 60
Discussion 61
Brachyury has emerged as a target for the treatment of chordoma. The finding that ATRA results in 62 the reduction of TBXT (Brachyury) mRNA brings ATRA into consideration as a repurposed therapeutic 63
intervention. Here we have added important additional insight into the relationship between the 64 ATRA response pathway and Brachyury in chordoma cells. Our findings support a model in which 65 ATRA activates differentiation, which involves the shutdown of Brachyury activity. Indeed, such a 66 model is supported by work in zebrafish notochord development, where ATRA treatment rapidly 67 reduces levels of transcripts from the zebrafish orthologue gene, ntl (Martin & Kimelman, 2010) . 68
Conclusions 69
This study demonstrates that ATRA treatment lowers Brachyury levels, consistent with mRNA 70 studies (Aydemir et al., 2012) . The extent to which ATRA influences Brachyury levels varies between 71 chordoma cells types, so targeting Brachyury up-stream regulatory pathways with ATRA might not 72 prove to be universally effective. It remains unclear if Brachyury is directly regulated by an ATRA 73 response pathway, but we can conclude that response to ATRA cellular changes are highly similar to 74 those observed for specific Brachyury depletion. Thus, repurposing of ATRA to target a Brachyury 75 activating pathway is an important consideration. 76
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